Maribavir: First Approval
Maribavir (LIVTENCITY TM ), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (...
Gespeichert in:
| Veröffentlicht in: | Drugs (New York, N.Y.) N.Y.), 2022-02, Vol.82 (3), p.335-340 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 3 |
| container_start_page | 335 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 82 |
| creator | Kang, Connie |
| description | Maribavir (LIVTENCITY
TM
), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections. |
| doi_str_mv | 10.1007/s40265-022-01677-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2628301843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2635542067</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-45a08391e687e168a8c2fda365e4b41fdcb52fab373d4c75ca9b459e3db1cebd3</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gB5E8OIlmsnnxlspVoWKFz2HJJuVLdtuTboF_72pWxU8eBqGeead4UHoDMg1EKJuEidUCkwoxQSkUpjvoSGA0hi0IPtoSAhQLKVUA3SU0nzbaqEP0YAJ4EoDG6LTJxtrZzd1vL2Y1jGtL8arVWw3tjlGB5VtUjjZ1RF6nd69TB7w7Pn-cTKeYc-UWGMuLCmYhiALFUAWtvC0Ki2TInDHoSq9E7SyjilWcq-Et9pxoQMrHfjgSjZCV31uPvvehbQ2izr50DR2GdouGSppwQgUnGX08g86b7u4zN9lignBKZEqU7SnfGxTiqEyq1gvbPwwQMxWnOnFmSzOfIkzPC-d76I7twjlz8q3qQywHkh5tHwL8ff2P7GfJr92Tg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2635542067</pqid></control><display><type>article</type><title>Maribavir: First Approval</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kang, Connie</creator><creatorcontrib>Kang, Connie</creatorcontrib><description>Maribavir (LIVTENCITY
TM
), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-022-01677-4</identifier><identifier>PMID: 35147913</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>AdisInsight Report ; Adult ; Adults ; Anticonvulsants ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; Benzimidazoles - pharmacology ; Benzimidazoles - therapeutic use ; Child ; Cidofovir ; Cytomegalovirus ; Cytomegalovirus Infections - drug therapy ; Disease prevention ; Drug dosages ; Drug Resistance, Viral ; Enzyme inhibitors ; Enzymes ; Foscarnet ; Ganciclovir ; Humans ; Infections ; Internal Medicine ; Kinases ; Medicine ; Medicine & Public Health ; Mutation ; Patients ; Pediatrics ; Pharmaceutical industry ; Pharmacology/Toxicology ; Pharmacotherapy ; Plasma ; Proteins ; Ribonucleosides - pharmacology ; Ribonucleosides - therapeutic use ; Transplants & implants</subject><ispartof>Drugs (New York, N.Y.), 2022-02, Vol.82 (3), p.335-340</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</rights><rights>Copyright Springer Nature B.V. Feb 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-45a08391e687e168a8c2fda365e4b41fdcb52fab373d4c75ca9b459e3db1cebd3</citedby><cites>FETCH-LOGICAL-c375t-45a08391e687e168a8c2fda365e4b41fdcb52fab373d4c75ca9b459e3db1cebd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40265-022-01677-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40265-022-01677-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35147913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Connie</creatorcontrib><title>Maribavir: First Approval</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Maribavir (LIVTENCITY
TM
), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.</description><subject>AdisInsight Report</subject><subject>Adult</subject><subject>Adults</subject><subject>Anticonvulsants</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Benzimidazoles - pharmacology</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Child</subject><subject>Cidofovir</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus Infections - drug therapy</subject><subject>Disease prevention</subject><subject>Drug dosages</subject><subject>Drug Resistance, Viral</subject><subject>Enzyme inhibitors</subject><subject>Enzymes</subject><subject>Foscarnet</subject><subject>Ganciclovir</subject><subject>Humans</subject><subject>Infections</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Plasma</subject><subject>Proteins</subject><subject>Ribonucleosides - pharmacology</subject><subject>Ribonucleosides - therapeutic use</subject><subject>Transplants & implants</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LAzEQhoMotlZ_gB5E8OIlmsnnxlspVoWKFz2HJJuVLdtuTboF_72pWxU8eBqGeead4UHoDMg1EKJuEidUCkwoxQSkUpjvoSGA0hi0IPtoSAhQLKVUA3SU0nzbaqEP0YAJ4EoDG6LTJxtrZzd1vL2Y1jGtL8arVWw3tjlGB5VtUjjZ1RF6nd69TB7w7Pn-cTKeYc-UWGMuLCmYhiALFUAWtvC0Ki2TInDHoSq9E7SyjilWcq-Et9pxoQMrHfjgSjZCV31uPvvehbQ2izr50DR2GdouGSppwQgUnGX08g86b7u4zN9lignBKZEqU7SnfGxTiqEyq1gvbPwwQMxWnOnFmSzOfIkzPC-d76I7twjlz8q3qQywHkh5tHwL8ff2P7GfJr92Tg</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Kang, Connie</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20220201</creationdate><title>Maribavir: First Approval</title><author>Kang, Connie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-45a08391e687e168a8c2fda365e4b41fdcb52fab373d4c75ca9b459e3db1cebd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>AdisInsight Report</topic><topic>Adult</topic><topic>Adults</topic><topic>Anticonvulsants</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Benzimidazoles - pharmacology</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Child</topic><topic>Cidofovir</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus Infections - drug therapy</topic><topic>Disease prevention</topic><topic>Drug dosages</topic><topic>Drug Resistance, Viral</topic><topic>Enzyme inhibitors</topic><topic>Enzymes</topic><topic>Foscarnet</topic><topic>Ganciclovir</topic><topic>Humans</topic><topic>Infections</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Plasma</topic><topic>Proteins</topic><topic>Ribonucleosides - pharmacology</topic><topic>Ribonucleosides - therapeutic use</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Connie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Connie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maribavir: First Approval</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>82</volume><issue>3</issue><spage>335</spage><epage>340</epage><pages>335-340</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Maribavir (LIVTENCITY
TM
), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35147913</pmid><doi>10.1007/s40265-022-01677-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2022-02, Vol.82 (3), p.335-340 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2628301843 |
| source | MEDLINE; SpringerLink Journals |
| subjects | AdisInsight Report Adult Adults Anticonvulsants Antiviral Agents - pharmacology Antiviral Agents - therapeutic use Benzimidazoles - pharmacology Benzimidazoles - therapeutic use Child Cidofovir Cytomegalovirus Cytomegalovirus Infections - drug therapy Disease prevention Drug dosages Drug Resistance, Viral Enzyme inhibitors Enzymes Foscarnet Ganciclovir Humans Infections Internal Medicine Kinases Medicine Medicine & Public Health Mutation Patients Pediatrics Pharmaceutical industry Pharmacology/Toxicology Pharmacotherapy Plasma Proteins Ribonucleosides - pharmacology Ribonucleosides - therapeutic use Transplants & implants |
| title | Maribavir: First Approval |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T05%3A31%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maribavir:%20First%20Approval&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=Kang,%20Connie&rft.date=2022-02-01&rft.volume=82&rft.issue=3&rft.spage=335&rft.epage=340&rft.pages=335-340&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-022-01677-4&rft_dat=%3Cproquest_cross%3E2635542067%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2635542067&rft_id=info:pmid/35147913&rfr_iscdi=true |